The European Association of Urology upgrades UroLift® System trial data to its highest possible classification - Level 1A - in its Guidelines
March 14, 2016
MUNICH, GERMANY – March 14, 2016 – The UroLift® System treatment for enlarged prostate was showcased today at the European Association of Urology...
Read MoreNeoTract, Inc. Announces First Patients Enrolled in New Study to Expand UroLift System Indication
March 7, 2016
PLEASANTON, Calif. -- NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, today announced that the...
Read MoreThe “Other” Prostate Condition: Benign Prostatic Hyperplasia Affects Millions of U.S. Men, Can Severely Impact Quality of Life
November 10, 2015
PLEASANTON, Calif. and Washington, D.C. – Lack of awareness about a common health condition may be causing millions of men to suffer unnecessarily....
Read MoreNICE Evaluation and Tariff Code Announcements to Increase UroLift® System Availability in UK NHS Patients with Enlarged Prostate
September 17, 2015
PLEASANTON, CA, US - NeoTract, Inc., today welcomed the announcement by NICE that its UroLift® System (Prostatic Urethral Lift) to treat an enlarged...
Read MoreNeoTract, Inc. Receives Edison Award for Innovative Treatment for Men with Enlarged Prostate
April 24, 2015
PLEASANTON, Calif. – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, announced today the company...
Read MoreNICE gives go ahead to NeoTract’s groundbreaking UroLift® Prostate Implant that can preserve sexual function while offering urinary symptom relief for millions of men affected by enlarged prostates
January 29, 2014
PLEASANTON, CA, US, - NeoTract, Inc., today announced that the UK’s National Institute for Health and Care Excellence (NICE) has issued an...
Read MoreNeoTract’s UroLift® Prostate Implant Demonstrates Strong Safety and Efficacy Benefits with Minimally Invasive BPH Treatment
May 7, 2013
PLEASANTON, CA, - NeoTract, Inc., today announced the successful results of the 206-patient L.I.F.T. IDE Study, a multi-center, randomized, blinded...
Read More
